Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Higano says radium-223 (Xofigo), a radium isotope approved by the FDA to treat mCRPC, is unique from other therapies in cancer overall. Results from a phase III study showed that patients who received radium-223 had higher overall survival (OS) compared to patients who did not receive the therapy.

Radium-223 can also benefit patients who may have skeletal metastases, fractures, or require external beam radiation, Higano says.

Radium-223 is an exciting new tool and researchers are exploring how it can be used with other novel therapies that have been developed in the last few years.

Videos

Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).


Celestia S. Higano

Articles

Dr. Higano on Radium-223 for mCRPC